Alnylam Archives -

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

Phil Taylor Alnylam, HEOR, hypertension, innovation passport, MHRA, NHS, regulatory, UK, zilebesiran 0 Comment

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport‘, a designation designed

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

https://pharmaphorum.com/news/mhra-gives-alnylam-innovation-passport-for-hypertension-drug-zilebesiran/

Market Access/ News/ News

Alnylam gets NICE backing for porphyria therapy Givlaari

Phil Taylor Alnylam, Givlaari, HEOR, NICE, porphyria, rare disease 0 Comment

UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and

Alnylam gets NICE backing for porphyria therapy Givlaari

https://pharmaphorum.com/news/alnylam-gets-nice-backing-for-porphyria-therapy-givlaari/

Digital/ News/ News

Alnylam launches digital tool for ATTR amyloidosis patients

Phil Taylor Alnylam, ATTR amyloidosis, digital, digital health, Onpattro 0 Comment

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to

Alnylam launches digital tool for ATTR amyloidosis patients

https://pharmaphorum.com/news/alnylam-launches-digital-tool-for-aatr-amyloidosis-patients/

Market Access/ News/ News

Novartis tries to rescue stalled inclisiran filing with FDA

Phil Taylor Alnylam, cardiology, cholesterol, fda, inclisiran, Novartis 0 Comment

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on

Novartis tries to rescue stalled inclisiran filing with FDA

https://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/

News/ News/ R&D

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

Phil Taylor Alnylam, Dupixent, Haematology, haemophilia A, haemophilia B, Sanofi 0 Comment

Sanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

https://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/

Market Access/ News/ News

FDA rejects Novartis’ cholesterol drug after factory inspection issue

Richard Staines Alnylam, cardiology, fda, inclisiran, Novartis 0 Comment

Novartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster

FDA rejects Novartis’ cholesterol drug after factory inspection issue

https://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/

Market Access/ News/ News

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

Richard Staines Alnylam, Dicerna, pricing, Rare diseases, regulation 0 Comment

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1),

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

https://pharmaphorum.com/news/fda-approves-alynlams-ultra-rare-disease-drug-oxlumo/

News/ News/ R&D

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Richard Staines Alnylam, haemophilia, Rare diseases, Roche, Sanofi 0 Comment

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

https://pharmaphorum.com/news/sanofi-alnylans-haemophilia-drug-hits-another-safety-speed-bump/

Podcast/ R&D/ Views & Analysis/ Views and analysis

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

Dominic Tyer Alnylam, coronavirus, COVID-19, gene silencing, podcast, RNAi 0 Comment

Alnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

https://pharmaphorum.com/r-d/alnylam-gene-silencing-biotech-podcast/

Trending

Alnylam

Login